AimedBio and Boehringer Ingelheim initiate Phase I study of antibody-drug conjugate BI 4060107

Posted on by sHq_LoGiNz

SEOUL, South Korea–(BUSINESS WIRE)– #ADC–AimedBio, a clinical-stage biotech company, announces first patient dosed in Phase I trial of ADC candidate BI 4060107.

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance (opens in a new tab)
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.